Quinidine 是一种抗心律失常剂。Quinidine 是一种有效的、具有口服活性的、选择性的细胞色素 P450db (cytochrome P450db) 抑制剂,也是 K+通道 (K+channel) 的有效阻断剂,其IC50值为 19.9 μM,也可诱导凋亡。Quinidine 也可用作疟疾的研究。
生物活性 | Quinidine is an antiarrhythmic agent. Quinidine is a potent, orally active, selectivecytochrome P450dbinhibitor. Quinidine is also aK+channelblocker with anIC50of 19.9 μM, and can induceapoptosis. Quinidine can be used for malaria research[1][2][3][4]. |
体外研究 (In Vitro) | Quinidine shows cytotoxicity against MES-SA cells, and induces apoptosis[4].
Cell Cytotoxicity Assay[4] Cell Line: | MES-SA and MESSA/DX5 cells | Concentration: | 10 μM | Incubation Time: | 24 hours | Result: | Showed cytotoxicity against MES-SA cells in a concentration-dependent manner. |
Apoptosis Analysis[4] Cell Line: | MES-SA and MESSA/DX5 cells | Concentration: | 10 μM | Incubation Time: | 24 hours | Result: | Increased the apoptotic portion sub-G1 DNA contents induced by paclitaxel, while paclitaxel had no effect on sub-G1 DNA contents undergoing apoptosis. |
|
体内研究 (In Vivo) | Quinidine shows effects on the PTZ-induced seizure threshold[5].
Animal Model: | Male mice of the NMRI strain (age 5-6 weeks and weight 25-30 g)[5 | Dosage: | 10, 20, and 30 mg/kg | Administration: | Intraperitoneal injection; 10, 20, and 30 mg/kg; once | Result: | Increased the threshold dose for the onset to tonic hind limb extension at a dose of 30 mg/kg, compared to the saline-treated control group (p<0.05). |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | - Alkaloids
- Quinoline Alkaloids
|
来源 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(154.12 mM) Ethanol : 14.29 mg/mL(44.05 mM;ultrasonic and warming and heat to 60℃) H2O : 0.67 mg/mL(2.07 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 3.0824 mL | 15.4121 mL | 30.8242 mL | 5 mM | 0.6165 mL | 3.0824 mL | 6.1648 mL | 10 mM | 0.3082 mL | 1.5412 mL | 3.0824 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light, stored under nitrogen)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (7.71 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (7.71 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (7.71 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|